Neurocrine Biosciences Company Profile (NASDAQ:NBIX)

About Neurocrine Biosciences

Neurocrine Biosciences logoNeurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company's two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women's health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: NBIX
  • CUSIP: 64125C10
Key Metrics:
  • Previous Close: $53.36
  • 50 Day Moving Average: $50.45
  • 200 Day Moving Average: $46.60
  • 52-Week Range: $31.25 - $58.46
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -28.69
  • P/E Growth: 3.02
  • Market Cap: $4.63B
  • Outstanding Shares: 86,751,000
  • Beta: 0.47
  • Return on Equity: -29.61%
  • Return on Assets: -26.57%
  • Current Ratio: 14.58%
  • Quick Ratio: 14.58%
Additional Links:
Companies Related to Neurocrine Biosciences:

Analyst Ratings

Consensus Ratings for Neurocrine Biosciences (NASDAQ:NBIX) (?)
Ratings Breakdown: 10 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $64.80 (21.44% upside)

Analysts' Ratings History for Neurocrine Biosciences (NASDAQ:NBIX)
DateFirmActionRatingPrice TargetDetails
9/23/2016BMO Capital MarketsReiterated RatingOutperform$66.00View Rating Details
9/23/2016Jefferies GroupReiterated RatingBuy$61.00View Rating Details
9/22/2016Piper Jaffray Cos.Reiterated RatingOverweight$96.00View Rating Details
8/30/2016Robert W. BairdReiterated RatingOutperform$66.00View Rating Details
8/5/2016Cowen and CompanyReiterated RatingBuy$65.00View Rating Details
8/5/2016HC WainwrightReiterated RatingBuyView Rating Details
6/1/2016Leerink SwannReiterated RatingOutperform$63.00View Rating Details
5/4/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
11/2/2015NomuraBoost Price TargetBuy$34.00 -> $43.00View Rating Details
11/2/2015Deutsche Bank AGBoost Price TargetBuy$35.00 -> $45.00View Rating Details
3/4/2015Barclays PLCInitiated CoverageOverweight$60.00View Rating Details
2/5/2015Royal Bank Of CanadaInitiated CoverageOutperform$40.00View Rating Details
11/4/2014MKM PartnersReiterated RatingBuy$20.00 -> $22.00View Rating Details
(Data available from 9/27/2014 forward)


Earnings History for Neurocrine Biosciences (NASDAQ:NBIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2016Q1($0.29)($0.22)$15.43 million$15.00 millionViewN/AView Earnings Details
2/11/2016Q415($0.32)($0.34)$3.33 millionViewListenView Earnings Details
10/29/2015Q315($0.25)($0.40)$6.66 millionViewListenView Earnings Details
7/29/2015Q2($0.29)($0.28)$0.41 millionViewListenView Earnings Details
4/30/2015Q115($0.30)($0.01)$19.76 millionViewN/AView Earnings Details
2/9/2015Q414($0.24)($0.26)ViewN/AView Earnings Details
11/3/2014Q314($0.21)($0.21)ViewN/AView Earnings Details
8/6/2014Q214($0.18)($0.18)$0.12 millionViewN/AView Earnings Details
4/30/2014Q114($0.19)($0.17)ViewN/AView Earnings Details
2/6/2014Q413($0.17)($0.16)$0.79 million$0.73 millionViewN/AView Earnings Details
10/29/2013Q313($0.20)($0.17)$0.79 million$0.73 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.20)($0.18)$0.77 million$0.73 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.18)$1.07 million$0.70 millionViewListenView Earnings Details
2/8/2013Q4 2012($0.08)$0.14$9.43 million$21.90 millionViewListenView Earnings Details
10/31/2012Q312($0.05)($0.05)$10.28 million$9.40 millionViewN/AView Earnings Details
7/31/2012($0.03)($0.01)ViewN/AView Earnings Details
5/2/2012($0.01)ViewN/AView Earnings Details
10/31/2011$0.19$0.56ViewN/AView Earnings Details
7/28/2011$0.04$0.04ViewN/AView Earnings Details
5/3/2011$0.05$0.05ViewN/AView Earnings Details
2/10/2011$0.04$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Neurocrine Biosciences (NASDAQ:NBIX)
Current Year EPS Consensus Estimate: $-1.92 EPS
Next Year EPS Consensus Estimate: $-1.86 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.26)($0.25)($0.26)
Q2 20162($0.52)($0.47)($0.50)
Q3 20162($0.56)($0.55)($0.56)
Q4 20163($0.65)($0.62)($0.64)
(Data provided by Zacks Investment Research)


Dividend History for Neurocrine Biosciences (NASDAQ:NBIX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Neurocrine Biosciences (NASDAQ:NBIX)
Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 96.70%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2016Malcolm Lloyd-SmithInsiderSell9,000$50.00$450,000.00View SEC Filing  
8/15/2016Christopher Flint ObrienInsiderSell12,500$48.73$609,125.00View SEC Filing  
8/8/2016Corinne H NevinnyDirectorSell5,000$48.54$242,700.00View SEC Filing  
5/25/2016Richard F PopsDirectorSell15,000$46.72$700,800.00View SEC Filing  
5/16/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  
4/11/2016Kyle GanoInsiderSell41,770$44.02$1,838,715.40View SEC Filing  
4/6/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  
2/3/2016Haig P BozigianInsiderSell1,375$38.13$52,428.75View SEC Filing  
2/3/2016Kevin Charles GormanCEOSell3,125$38.04$118,875.00View SEC Filing  
2/3/2016Timothy P CoughlinCFOSell1,500$38.06$57,090.00View SEC Filing  
1/19/2016Haig P BozigianInsiderSell1,625$46.77$76,001.25View SEC Filing  
1/19/2016Kevin Charles GormanCEOSell3,750$46.70$175,125.00View SEC Filing  
1/19/2016Timothy P CoughlinCFOSell1,750$46.69$81,707.50View SEC Filing  
1/11/2016Haig P BozigianInsiderSell1,625$44.25$71,906.25View SEC Filing  
1/11/2016Kevin Charles GormanCEOSell3,750$44.17$165,637.50View SEC Filing  
1/11/2016Timothy P CoughlinCFOSell1,750$44.25$77,437.50View SEC Filing  
11/27/2015Dimitri E. GrigoriadisinsiderSell10,000$57.50$575,000.00View SEC Filing  
11/9/2015Darin LippoldtinsiderSell23,761$52.92$1,257,432.12View SEC Filing  
10/16/2015Haig P BozigianInsiderSell25,000$47.78$1,194,500.00View SEC Filing  
10/16/2015Kevin Charles GormanCEOSell33,500$47.77$1,600,295.00View SEC Filing  
9/18/2015Gary A. LyonsDirectorSell15,000$54.89$823,350.00View SEC Filing  
7/20/2015Dimitri E GrigoriadisInsiderSell19,646$55.00$1,080,530.00View SEC Filing  
7/20/2015Timothy P CoughlinCFOSell20,000$55.00$1,100,000.00View SEC Filing  
7/13/2015Dimitri E GrigoriadisInsiderSell10,000$50.00$500,000.00View SEC Filing  
7/13/2015Timothy P CoughlinCFOSell20,000$50.00$1,000,000.00View SEC Filing  
6/23/2015W Thomas MitchellDirectorSell15,000$49.35$740,250.00View SEC Filing  
6/8/2015Christopher Flint ObrienInsiderSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Timothy P CoughlinCFOSell60,000$45.08$2,704,800.00View SEC Filing  
3/24/2015Gary A LyonsDirectorSell30,000$41.53$1,245,900.00View SEC Filing  
3/24/2015Kevin Charles GormanCEOSell40,000$41.53$1,661,200.00View SEC Filing  
2/10/2015Dimitri E GrigoriadisInsiderSell20,000$35.00$700,000.00View SEC Filing  
1/16/2015Christopher Flint ObrienInsiderSell1,750$30.79$53,882.50View SEC Filing  
1/16/2015Kevin Charles GormanCEOSell3,750$30.79$115,462.50View SEC Filing  
1/12/2015Kevin Charles GormanCEOSell3,750$28.43$106,612.50View SEC Filing  
1/12/2015Kyle GanoInsiderSell1,250$28.41$35,512.50View SEC Filing  
1/12/2015Timothy P CoughlinCFOSell1,750$28.37$49,647.50View SEC Filing  
1/8/2015Dimitri E GrigoriadisInsiderSell30,000$27.35$820,500.00View SEC Filing  
1/8/2015Kevin Charles GormanCEOSell25,000$27.39$684,750.00View SEC Filing  
1/8/2015Timothy P CoughlinCFOSell10,000$27.25$272,500.00View SEC Filing  
1/5/2015Dimitri E GrigoriadisInsiderSell2,500$22.76$56,900.00View SEC Filing  
1/2/2015W Thomas MitchellDirectorSell8,000$22.79$182,320.00View SEC Filing  
12/19/2014Christopher Flint ObrienInsiderSell20,000$24.02$480,400.00View SEC Filing  
12/19/2014Kevin Charles GormanCEOSell70,000$23.41$1,638,700.00View SEC Filing  
12/19/2014Timothy P CoughlinCFOSell30,000$23.46$703,800.00View SEC Filing  
12/17/2014Kyle GanoInsiderSell4,957$22.50$111,532.50View SEC Filing  
12/15/2014Dimitri E GrigoriadisInsiderSell12,794$22.35$285,945.90View SEC Filing  
12/12/2014Kyle GanoInsiderSell4,043$22.50$90,967.50View SEC Filing  
12/11/2014Christopher Flint ObrienInsiderSell40,000$21.82$872,800.00View SEC Filing  
12/10/2014Timothy P CoughlinCFOSell20,000$21.48$429,600.00View SEC Filing  
12/10/2014W Thomas MitchellDirectorSell7,000$21.90$153,300.00View SEC Filing  
11/28/2014Timothy P CoughlinCFOSell10,000$20.14$201,400.00View SEC Filing  
11/24/2014Christopher Flint ObrienInsiderSell5,463$19.53$106,692.39View SEC Filing  
10/31/2014Timothy P CoughlinCFOSell10,000$19.00$190,000.00View SEC Filing  
10/30/2014Timothy P CoughlinCFOSell20,000$18.31$366,200.00View SEC Filing  
10/1/2014W Thomas MitchellDirectorSell1,275$15.50$19,762.50View SEC Filing  
9/15/2014Gary A LyonsDirectorSell20,000$15.66$313,200.00View SEC Filing  
1/17/2014Dimitri GrigoriadisInsiderSell25,000$20.00$500,000.00View SEC Filing  
1/10/2014Christopher Flint ObrienInsiderSell6,750$18.88$127,440.00View SEC Filing  
1/10/2014Kevin Charles GormanCEOSell3,750$18.57$69,637.50View SEC Filing  
1/10/2014Timothy CoughlinCFOSell1,750$18.56$32,480.00View SEC Filing  
1/7/2014Dimitri GrigoriadisInsiderSell25,000$17.50$437,500.00View SEC Filing  
1/7/2014Kevin Charles GormanCEOSell108,000$16.76$1,810,080.00View SEC Filing  
1/7/2014Timothy CoughlinCFOSell70,000$16.75$1,172,500.00View SEC Filing  
9/4/2013Kyle GanoInsiderSell2,400$15.61$37,464.00View SEC Filing  
9/3/2013Christopher Flint ObrienInsiderSell5,000$16.00$80,000.00View SEC Filing  
8/21/2013Haig BozigianInsiderSell13,999$15.04$210,544.96View SEC Filing  
8/21/2013Timothy CoughlinCFOSell19,035$15.05$286,476.75View SEC Filing  
8/6/2013W Thomas MitchellDirectorSell1,531$14.70$22,505.70View SEC Filing  
8/5/2013Haig BozigianInsiderSell11,001$15.00$165,015.00View SEC Filing  
8/5/2013Timothy CoughlinCFOSell10,965$14.99$164,365.35View SEC Filing  
7/12/2013Christopher Flint ObrienInsiderSell5,000$14.50$72,500.00View SEC Filing  
6/28/2013Christopher Flint ObrienInsiderSell11,357$13.33$151,388.81View SEC Filing  
6/27/2013Haig P BozigianInsiderSell8,000$13.00$104,000.00View SEC Filing  
6/21/2013Dimitri E GrigoriadisInsiderSell46,837$12.51$585,930.87View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Neurocrine Biosciences (NASDAQ:NBIX)
DateHeadline logoNEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Finan (NASDAQ:NBIX) - September 23 at 5:55 PM
News IconNeurocrine Biosciences Given Buy Rating at Robert W. Baird (NBIX ... - Petro Global News 24 (NASDAQ:NBIX) - September 22 at 6:01 PM logoPiper Jaffray Co. Shows Optimism On Neurocrine Biosciences Inc (NBIX) Stock - TCC (NASDAQ:NBIX) - September 22 at 6:01 PM logoPiper Jaffray Shows Optimism On Neurocrine Biosciences, Inc. (NBIX) Stock (NASDAQ:NBIX) - September 22 at 11:05 AM logoGeneric Drugs Stocks on Investors' Radar -- Zoetis, Sophiris Bio, Rigel Pharma, and Neurocrine Biosciences (NASDAQ:NBIX) - September 20 at 11:35 AM
News IconNeurocrine Biosciences, Inc. (NBIX) Given “Buy” Rating at ... - DailyQuint (NASDAQ:NBIX) - September 19 at 6:21 PM
News IconWhat is the Street Saying About Neurocrine Biosciences, Inc. (NASDAQ:NBIX)? - Frisco Fastball (NASDAQ:NBIX) - September 19 at 10:48 AM
News IconStock Tracker: Earnings & Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Frisco Fastball (NASDAQ:NBIX) - September 19 at 10:48 AM logoNeurocrine Biosciences : Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia (NASDAQ:NBIX) - September 17 at 10:48 AM logoNeurocrine Biosciences To Participate In Morgan Stanley Conference At 11:10 AM (NASDAQ:NBIX) - September 13 at 11:09 AM logoInvestor's Alert: FleetCor Technologies, Inc. (FLT), Neurocrine Biosciences Inc. (NBIX), Bank of the Ozarks, Inc. (OZRK) - iStreetWire (NASDAQ:NBIX) - September 11 at 10:29 AM
News IconNeurocrine Biosciences, Inc. (NASDAQ:NBIX): What is the Sell-side Making of this Stock? - National Daily Press (NASDAQ:NBIX) - September 11 at 10:29 AM logoNeurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference - PR Newswire (press release) (NASDAQ:NBIX) - September 8 at 10:09 AM logoNeurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference (NASDAQ:NBIX) - September 7 at 6:30 PM logoNeurocrine Biosciences to Present at the Baird 2016 Healthcare ... - PR Newswire (press release) (NASDAQ:NBIX) - September 1 at 6:17 PM
News IconShares Slipping Lower Over the Past Month: Neurocrine Biosciences Inc. (NASDAQ:NBIX) - Post News (NASDAQ:NBIX) - September 1 at 6:17 PM logoNeurocrine Biosciences to Present at the Baird 2016 Healthcare Conference (NASDAQ:NBIX) - September 1 at 6:17 PM logoNeurocrine Biosciences (NBIX) Announces Conditional FDA Acceptance of Proposed Valbenazine Brand Name (NASDAQ:NBIX) - September 1 at 9:31 AM logoNeurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor Valbenazine (NASDAQ:NBIX) - September 1 at 9:31 AM
News IconNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares in Focus ... - Post News (NASDAQ:NBIX) - August 31 at 11:22 AM logoNeurocrine Biosciences (NBIX) Announces Submission of Valbenazine NDA as Tardive Dyskinesia Treatment (NASDAQ:NBIX) - August 29 at 6:10 PM logoNeurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia (NASDAQ:NBIX) - August 29 at 6:10 PM
News IconNeurocrine Biosciences Inc.'s (NBIX): Seeing Active Stock of ... - Hot Stocks Point (NASDAQ:NBIX) - August 28 at 5:41 PM
News IconNeurocrine Biosciences, Inc. (NASDAQ:NBIX): What Are Analysts Saying Now? - Post News (NASDAQ:NBIX) - August 20 at 10:28 AM logoETF’s with exposure to Neurocrine Biosciences, Inc. : August 12, 2016 (NASDAQ:NBIX) - August 12 at 6:27 PM logoNEUROCRINE BIOSCIENCES INC Financials (NASDAQ:NBIX) - August 11 at 6:50 PM logoNeurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : NBIX-US : August 11, 2016 (NASDAQ:NBIX) - August 11 at 9:36 AM logoEARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q2 Earnings Report (NASDAQ:NBIX) - August 4 at 9:32 AM logoNeurocrine Biosciences Inc.: Neurocrine Biosciences Reports Second Quarter 2016 Results (NASDAQ:NBIX) - August 4 at 9:32 AM logoNeurocrine Biosciences Reports Second Quarter 2016 Results (NASDAQ:NBIX) - August 4 at 9:32 AM logoEdited Transcript of NBIX earnings conference call or presentation 3-Aug-16 9:00pm GMT (NASDAQ:NBIX) - August 4 at 9:32 AM logoNeurocrine reports 2Q loss (NASDAQ:NBIX) - August 3 at 6:43 PM logoQ2 2016 Neurocrine Biosciences Inc Earnings Release - After Market Close (NASDAQ:NBIX) - August 3 at 9:42 AM logoAnalysts Observable Stocks: Luminex Corporation (NASDAQ:LMNX) , Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Street Updates (NASDAQ:NBIX) - August 1 at 11:01 AM
News IconBulls and Bear in Spotlight: Citigroup Inc. (NYSE:C), Neurocrine Biosciences Inc. (NASDAQ:NBIX), Digital Realty ... - Seneca Globe (NASDAQ:NBIX) - July 29 at 9:25 AM logoNeurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome (NASDAQ:NBIX) - July 28 at 4:28 PM logo4:04 pm Neurocrine Biosci initiates a Phase II clinical trial for NBI-98854 in children, adolescents and adults with Tourette syndrome (NASDAQ:NBIX) - July 28 at 4:04 PM logoShort Interest In Neurocrine Biosciences Jumps 14% (NASDAQ:NBIX) - July 28 at 9:36 AM logoNeurocrine Biosciences Announces Conference Call and Webcast ... - PR Newswire (press release) (NASDAQ:NBIX) - July 27 at 6:43 PM logoAnalysts Observing Stocks: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Neurocrine Biosciences, Inc ... - Street Updates (NASDAQ:NBIX) - July 27 at 6:43 PM logoNeurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2016 Results (NASDAQ:NBIX) - July 27 at 1:38 PM logoNeurocrine Biosciences Larger Than S&P 500 Component CSRA (NASDAQ:NBIX) - July 25 at 6:28 PM
News IconShares Positive Over the Past Month: Neurocrine Biosciences Inc. (NASDAQ:NBIX) - TGP (NASDAQ:NBIX) - July 21 at 6:40 PM
News IconNeurocrine Biosciences, Inc. (NASDAQ:NBIX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:NBIX) - July 21 at 6:40 PM
News IconBlue Jay Capital Management LLC Increased Neurocrine Biosciences INC (NASDAQ:NBIX) by $6.10 Million as Shares ... - Consumer Eagle (NASDAQ:NBIX) - July 21 at 6:40 PM logoNeurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : July 20, 2016 (NASDAQ:NBIX) - July 20 at 1:11 PM logoNeurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : July 19, 2016 (NASDAQ:NBIX) - July 19 at 8:15 AM
News IconPerceptive Advisors LLC Increased Neurocrine Biosciences INC (NASDAQ:NBIX) by $8.77 Million as Shares Declined - Consumer Eagle (NASDAQ:NBIX) - July 18 at 6:30 PM
News IconAre Analysts Bullish Neurocrine Biosciences, Inc. (NASDAQ:NBIX) After Last Week? - Consumer Eagle (NASDAQ:NBIX) - July 18 at 6:30 PM
News IconNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Wall Street Analyst Recommendation Outlook - TGP (NASDAQ:NBIX) - July 18 at 6:30 PM


Neurocrine Biosciences (NASDAQ:NBIX) Chart for Tuesday, September, 27, 2016

Last Updated on 9/27/2016 by Staff